Cantargia 관리

관리 기준 확인 3/4

Cantargia CEO는 Goran Forsberg, Jun2014 에 임명되었습니다 의 임기는 10.42 년입니다. 총 연간 보상은 SEK 5.40M, 44% 로 구성됩니다. 44% 급여 및 56% 보너스(회사 주식 및 옵션 포함). 는 € 48.27K 가치에 해당하는 회사 주식의 0.17% 직접 소유합니다. 48.27K. 경영진과 이사회의 평균 재임 기간은 각각 2.3 년과 4.1 년입니다.

주요 정보

Goran Forsberg

최고 경영자

SEK 5.4m

총 보상

CEO 급여 비율	44.0%
CEO 임기	10.4yrs
CEO 소유권	0.2%
경영진 평균 재임 기간	2.3yrs
이사회 평균 재임 기간	4.1yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Goran Forsberg 의 보수는 Cantargia 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Sep 30 2024	n/a	n/a	-SEK 194m
Jun 30 2024	n/a	n/a	-SEK 228m
Mar 31 2024	n/a	n/a	-SEK 241m
Dec 31 2023	SEK 5m	SEK 2m	-SEK 280m
Sep 30 2023	n/a	n/a	-SEK 299m
Jun 30 2023	n/a	n/a	-SEK 293m
Mar 31 2023	n/a	n/a	-SEK 330m
Dec 31 2022	SEK 5m	SEK 2m	-SEK 372m
Sep 30 2022	n/a	n/a	-SEK 385m
Jun 30 2022	n/a	n/a	-SEK 419m
Mar 31 2022	n/a	n/a	-SEK 411m
Dec 31 2021	SEK 5m	SEK 2m	-SEK 367m
Sep 30 2021	n/a	n/a	-SEK 319m
Jun 30 2021	n/a	n/a	-SEK 255m
Mar 31 2021	n/a	n/a	-SEK 206m
Dec 31 2020	SEK 6m	SEK 2m	-SEK 173m
Sep 30 2020	n/a	n/a	-SEK 153m
Jun 30 2020	n/a	n/a	-SEK 139m
Mar 31 2020	n/a	n/a	-SEK 127m
Dec 31 2019	SEK 4m	SEK 2m	-SEK 111m
Sep 30 2019	n/a	n/a	-SEK 102m
Jun 30 2019	n/a	n/a	-SEK 98m
Mar 31 2019	n/a	n/a	-SEK 101m
Dec 31 2018	SEK 3m	SEK 1m	-SEK 91m
Sep 30 2018	n/a	n/a	-SEK 78m
Jun 30 2018	n/a	n/a	-SEK 68m
Mar 31 2018	n/a	n/a	-SEK 56m
Dec 31 2017	SEK 3m	SEK 1m	-SEK 60m

보상 대 시장: Goran 의 총 보상 ($USD 494.80K )은 German 시장에서 비슷한 규모의 회사의 평균 수준입니다( $USD 476.59K ).

보상과 수익: 회사가 수익성이 없는 동안 Goran 의 보상이 증가했습니다.

CEO

Goran Forsberg (61 yo)

10.4yrs

테뉴어

SEK 5,404,000

보상

Mr. Goran Forsberg has been Independent Director at Guard Therapeutics International AB (publ) since May 2019. He has been the Chief Executive Officer at Cantargia AB (publ) since June 2014. Mr. Forsberg s...

리더십 팀

이름	위치	테뉴어	보상	소유권
Goran Forsberg	Chief Executive Officer	10.4yrs	SEK 5.40m	0.17% € 48.3k
Thoas Fioretos	Founder & Scientific Advisor	no data	SEK 355.00k	데이터 없음
Marcus Järås	Founder & Scientific Advisor	no data	데이터 없음	데이터 없음
Kjell Sjöström	Founder	no data	데이터 없음	데이터 없음
Patrik Renblad	Chief Financial Officer	1.4yrs	데이터 없음	데이터 없음
David Liberg	Chief Scientific Officer	1.4yrs	데이터 없음	데이터 없음
Nina Valkama	Executive Assistant of Administration & Finance	2.9yrs	데이터 없음	데이터 없음
Dominique Tersago	Chief Medical Officer	2.3yrs	데이터 없음	데이터 없음
Antonius Berkien	Chief Business Officer	less than a year	데이터 없음	데이터 없음
Johanna Christensen	Financial Controller	2.9yrs	데이터 없음	데이터 없음

2.3yrs

평균 재임 기간

58.5yo

평균 연령

경험이 풍부한 관리: 7V3 의 관리팀은 경험 ( 2.3 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Gunnar Magnus Severus Persson	Independent Chairman of the Board	8.8yrs	SEK 854.00k	데이터 없음
Damian Marron	Independent Director	3.5yrs	SEK 350.00k	데이터 없음
Anders Martin-Lof	Independent Director	6.5yrs	SEK 473.00k	데이터 없음
Magnus Nilsson	Independent Director	3.5yrs	SEK 342.00k	데이터 없음
Flavia Borellini	Independent Director	4.1yrs	SEK 550.00k	데이터 없음

4.1yrs

평균 재임 기간

64yo

평균 연령

경험이 풍부한 이사회: 7V3 의 이사회는 경험(평균 재직 기간 4.1 년)으로 간주됩니다.

Cantargia 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

Cantargia AB (publ), Annual General Meeting, May 15, 2025

Cantargia Announces Resignation of Liselotte Larsson as Chief Operating Officer

Cantargia AB (Publ) Announces Appointment of Ton Berkien as Chief Business Officer, Effective October 1, 2024

Insufficient new directors

Cantargia AB (publ), Annual General Meeting, May 23, 2024

Cantargia AB (publ) Promotes David Liberg to Chief Scientific Officer

Recent updates

New major risk - Revenue and earnings growth

Cantargia AB (publ) to Report First Half, 2025 Results on Aug 21, 2025

Cantargia AB (publ), Annual General Meeting, May 15, 2025

Cantargia AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 169.910183 million.

Cantargia Presents Promising Preclinical Results on Nadunolimab with Antibody-Drug Conjugates At Major Immuno-Oncology Conference

Cantargia Reports New Results from Clinical Studies Investigating Nadunolimab in Several Forms of Cancer; Supporting Ongoing Strategies

Cantargia Reports New Positive Results on Biomarkers and Safety in CAN10 Phase 1 Clinical Study

Cantargia Announces the Publication of the Results Using Nadunolimab Combination Therapy in Advanced/Metastatic Pancreatic Cancer (PDAC) in the Scientific Journal Clinical Cancer Research

Cantargia AB (publ) to Report Q1, 2025 Results on May 13, 2025

Cantargia Announces New Data from Two Clinical Studies Strongly Support Nadunolimab Efficacy After Relapse on PD1-Inhibitors

Cantargia AB (publ) Reports Timelines for Nadunolimab Clinical Trials in Leukemia and Triple Negative Breast Cancer

Cantargia Announces Resignation of Liselotte Larsson as Chief Operating Officer

Cantargia AB (Publ) Reports Further Progress in Ongoing Phase 1 Clinical Trial with CAN10

Cantargia AB (Publ) Announces Appointment of Ton Berkien as Chief Business Officer, Effective October 1, 2024

Insufficient new directors

Cantargia Presents New Positive Clinical Data on Nadunolimab Counteracting Chemotherapy Induced Neuropathy

Forecast to breakeven in 2026

New major risk - Revenue and earnings growth

Cantargia Publishes New Data on the Can10 Antibody, Detailing Its Interaction with IL1RAP and Functional Inhibition

Cantargia AB (publ) Publishes Preclinical Data on the Potential of CAN10 in Systemic Sclerosis in A Leading Scientific Journal

Cantargia Publishes Data Highlighting the Potential of CAN10 in Atherosclerosis

Cantargia AB (publ) Reports Progress Towards Start of DOT-Sponsored Clinical Trial of Nadunolimab in Leukemia

Cantargia Reports New Data Highlighting Potential of CAN10 Antibody, Currently in Phase I Clinical Development, as Therapy in Systemic Sclerosis

Cantargia Reports New Preclinical Data on Antitumor Effects of nadunolimab in Pancreatic Cancer

Forecast to breakeven in 2026

New major risk - Financial position

Cantargia AB (publ) to Report Fiscal Year 2024 Results on Feb 21, 2025

Cantargia Reports US Regulatory Approval to Start Pancreatic Cancer Phase IIB Trial with Nadunolimab

Cantargia Reports New Data Reinforcing Nadunolimab as Cancer Combination Therapy

Cantargia Reports Phase I Clinical Progress in the CAN10 Project

Cantargia Reports New Preclinical Data Confirming the Potential of Nadunolimab and Can10

New major risk - Revenue and earnings growth

New major risk - Financial position

Cantargia AB (publ) to Report Q2, 2024 Results on Aug 28, 2024

Cantargia AB (publ), Annual General Meeting, May 23, 2024

New minor risk - Shareholder dilution

Cantargia Presents New Clinical Data Further Supporting Nadunolimab's Antitumor Activity and A Key Role of Its Target IL1RAP in Pancreatic Cancer

Cantargia Reports New Preclinical Data on nadunolimab Potential to Enhance Anti-Tumor Effect of Immunotherapy Presented at CRI-ENCI-AACR

Cantargia AB (publ) Announces New Nadunolimab Clinical Trial in Leukemia Financed by External US Grant

Cantargia AB (publ)Expands Clinical Pipeline and Starts Treatment in Second Program, CAN10, for Autoimmune Diseases

No longer forecast to breakeven

Cantargia AB (publ) to Report Q1, 2024 Results on May 21, 2024

Cantargia AB (publ) Receives Regulatory Approval to Start Phase I Clinical Trial for CAN10

Cantargia Publishes ASCO 2023 Poster on Promising Nadunolimab Efficacy in Non-Small Cell Lung Cancer

Cantargia AB (publ) Promotes David Liberg to Chief Scientific Officer

Cantargia Extends Development of Nadunolimab in Pancreatic Cancer with New Controlled Phase IIb Clinical Trial Following Strong Phase IIb Efficacy Results

Cantargia Appoints Patrik Renblad as Chief Financial Officer

Cantargia AB (publ) Successfully Concludes Toxicity Study with Can10 Antibody Ahead of Phase I Clinical Trial Application

Cantargia AB (Publ) Announces Nomination Committee Appointments

Cantargia's CAN10 Demonstrates Positive Activity in Systemic Sclerosis Models in New Data Presented At ACR Convergence 2022

Cantargia AB (Publ) Presents New Data At SITC 2022 Supporting Nadunolimab's Promising Antitumor Clinical Efficacy

Cantargia Reaches Recruitment Milestone and Focuses Nadunolimab Development on Upcoming Randomized Studies

Cantargia AB (publ) to Report Q2, 2023 Results on Aug 22, 2023

Cantargia Reports First Non-Squamous NSCLC Patient Treated with Nadunolimab, Keytruda® and Chemotherapy

Cantargia Reports Preclinical Data Demonstrating Unique Treatment Effects of nadunolimab on Pancreatic Cancer Stromal Cells

Cantargia AB (Publ) Publishes Preclinical Data on Strong Anti-Tumor Efficacy of Nadunolimab in Combination with Chemotherapy

Cantargia Reports New Positive Preclinical Efficacy Data for CAN10 Supporting Development in Myocarditis

Cantargia Receives USPTO Notice of Allowance for Composition of Matter Patent on Antibody CAN10

Cantargia AB (Publ) Announces Executive Changes

Cantargia Announces ASCO 2022 Presentation Strengthens Positive Phase IIa interim results for nadunolimab in NSCLC

Cantargia AB (publ) Presents Clinical Interim Results At ASCO 2022 Highlighting the Potential of Nadunolimab in Combination with Checkpoint Inhibitor

Cantargia AB (publ) Reports Positive Preclinical Effects in Atherosclerosis Demonstrating Potential of Can10 in Cardiovascular Disease

Forecast breakeven date pushed back to 2024

Forecast breakeven date pushed back to 2024

Cantargia Reports Positive Preclinical Efficacy Data for CAN10 Demonstrating Anti-Fibrotic and Anti-Inflammatory Effects in Systemic Sclerosis

Cantargia AB (Publ) Reports Encouraging New CAN10 Toxicology Results and Schedules Phase I Trial for 2023

Cantargia AB Reports Treatment of First Non-Squamous Non-Small Cell Lung Cancer Patient in New Arm of CANFOUR Study

Cantargia Reports Positive Safety Data from Cirifour Clinical Study on Nadunolimab and Pembrolizumab Combination

Cantargia AB (Publ) Reports Treatment of First Triple Negative Breast Cancer Patient in TRIFOUR Study